June 27, 2020
Following promising phase 1 testing, Mayo Clinic is launching phase 2 of a randomized clinical trial of stem cell treatment for patients with severe spinal cord injury. The clinical trial, known as CELLTOP, involves intrathecal injections of autologous adipose-derived stem cells.
"The field of spinal cord injury has seen advances in recent years, but nothing in the way of a significant paradigm shift. We currently rely on supportive care. Our hope is to alter the course of care for these patients in ways that improve their lives," says Mohamad Bydon, M.D., a neurosurgeon at Mayo Clinic in Rochester, Minnesota.
The first participant in the phase 1 trial was a superresponder who, after stem cell therapy, saw significant improvements in the function of his upper and lower extremities.
"Not every patient who receives stem cell treatment is going to be a superresponder. Among the 10 participants in our phase 1 study, we had some nonresponders and moderate responders," Dr. Bydon says. "One objective in our future studies is to delineate the optimal treatment protocols and understand why patients respond differently."
In CELLTOP phase 2, 40 patients will be randomized to receive stem cell treatment or best medical management. Patients randomized to the medical management arm will eventually cross over to the stem cell arm.
Study participants must be age 18 or older and have experienced traumatic spinal cord injury within the past year. The spinal cord injuries must be American Spinal Injury Association (ASIA) grade A or B.
The initial participant in CELLTOP phase 1 sustained a C3-4 ASIA grade A spinal cord injury. As described in the February 2020 issue of Mayo Clinic Proceedings, the neurological examination at the time of the injury revealed complete loss of motor and sensory function below the level of injury.
After undergoing urgent posterior cervical decompression and fusion, as well as physical and occupational therapy, the patient demonstrated improvement in motor and sensory function. But that progress plateaued six months after the injury.
Stem cells were injected nearly a year after his injury and several months after his improvement had plateaued. Clinical signs of efficacy in both motor and sensory function were observed at three, six, 12 and 18 months following the stem cell injection.
"Our patient also reported a strong improvement with his grip and pinch strength, as well as range of motion for shoulder flexion and abduction," Dr. Bydon says.
Spinal cord injury has a complex pathophysiology. After the primary injury, microenvironmental changes inhibit axonal regeneration. Stem cells can potentially provide trophic support to the injured spinal cord microenvironment by modulating the inflammatory response, increasing vascularization and suppressing cystic change.
"In the phase 2 study, we will begin to learn the characteristics of individuals who respond to the therapy in terms of their age, severity of injury and time since injury," says Anthony J. Windebank, M.D., a neurologist at Mayo's campus in Minnesota and director of the Regenerative Neurobiology Laboratory. "We will also use biomarker studies to learn about the characteristics of responders' cells. The next phase would be studying how we can modify everyone's cells to make them more like the cells of responders."
CELLTOP illustrates Mayo Clinic's commitment to regenerative medicine therapies for neurological care. "Our findings to date will be encouraging to patients with spinal cord injuries," Dr. Bydon says. "We are hopeful about the potential of stem cell therapy to become part of treatment algorithms that improve physical function for patients with these devastating injuries."
Bydon M, et al. CELLTOP clinical trial: First report from a phase I trial of autologous adipose tissue-derived mesenchymal stem cells in the treatment of paralysis due to traumatic spinal cord injury. Mayo Clinic Proceedings. 2020;95:406.
Regenerative Neurobiology Laboratory: Anthony J. Windebank. Mayo Clinic.
Read more here:
Stem cell treatment after spinal cord injury: The next steps - Mayo Clinic
- A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage - The Scientist - October 13th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 13th, 2022
- A history of blood cancer treatment - - pharmaphorum - September 16th, 2022
- What Are Zombie Cells? Here's How They Impact Aging - Prevention Magazine - September 8th, 2022
- ThreeSixty Journalism: Be The Match works to build equity in access to bone marrow and cord blood transplants - St. Paul Pioneer Press - September 8th, 2022
- Zhang and colleagues win an $11.2 million NIH program project grant (PPG) - News - University of Alabama at Birmingham - August 22nd, 2022
- Kyle Vining: Appointment to Faculty of Penn Dental Medicine and Penn School of Engineering and Applied Science - University of Pennsylvania - August 22nd, 2022
- Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 - Business Wire - August 14th, 2022
- Engineers develop new tool that will allow for more personalized cell therapies - UMN News - July 27th, 2022
- University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune - July 27th, 2022
- Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes - UCSF - July 27th, 2022
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 11th, 2022
- Witt Wolfpack: Family works out fundraising and awareness after La Jollan's ALS diagnosis - La Jolla Light - July 11th, 2022
- Pluripotent stem cellderived NK cells with high-affinity noncleavable ... - July 3rd, 2022
- Life-saving lecture: Auburn student uses lessons from class to help discover father's brain tumor - Office of Communications and Marketing - June 22nd, 2022
- Bluebird's future in balance as FDA weighs gene therapy approvals - BioPharma Dive - June 13th, 2022
- Be the Match is looking for more ethnically diverse donors to help patients with blood cancers and diseases - KARE11.com - June 4th, 2022
- Minnesota woman reunites with teenager she saved through Be The Match transplant - KSTP - April 19th, 2022
- Induced Pluripotent Stem Cells and Their Potential for ... - November 22nd, 2021
- Cells or drugs? The race to regenerate the heart - Scientific American - November 8th, 2021
- Four-year-old with rare disease finally gets historic gene therapy treatment - KARE11.com - October 5th, 2021
- Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors - Stockhouse - October 5th, 2021
- EDITORIAL: The need is vast. Consider becoming an organ donor. - Yahoo News - August 18th, 2021
- Our View: The need is vast. Consider becoming an organ donor. - PostBulletin.com - August 18th, 2021
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 11th, 2020
- COVID-19 and the trials of treatment | News, Sports, Jobs - Escanaba Daily Press - October 16th, 2020
- NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - Watauga Democrat - October 7th, 2020
- Berks County's first STEM-themed attraction opens, delights visitors young and old - Reading Eagle - October 7th, 2020
- Coronavirus Thursday update: UMN announces new stem cell ... - August 16th, 2020
- University of Minnesota launches stem cell trial against ... - August 16th, 2020
- University of Minnesota launches stem cell trial against severe COVID-19 - Minneapolis Star Tribune - August 16th, 2020
- Biotechnology Could Change the Cattle Industry. Will It Succeed? - Singularity Hub - August 16th, 2020
- Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update - Yahoo Finance - April 4th, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 4th, 2020
- Coronavirus is similar to SARS and causes infection through a heart regulating enzyme: Study - International Business Times, Singapore Edition - February 4th, 2020
- Why Sangamo Therapeutics Stock Sank Today - The Motley Fool - December 13th, 2019
- Hoeven's bill supports alternative therapy for veterans with PTSD, traumatic brain injury - Ripon Advance - October 1st, 2019
- Stem-cell treatment gives two brothers a future ... - March 3rd, 2019
- The Promise of Stem Cells | Stem Cell Institute ... - August 29th, 2018
- 2018 Regenerative Medicine Minnesota Research Awards - August 17th, 2018
- FDA cracks down on stem cell clinics - CNN - August 29th, 2017
- Mayo Clinic, University of Minnesota develop 'robocop' stem cells to fight cancer - Minneapolis Star Tribune - August 24th, 2017
- Cowboy Up Ride Against Cancer - Wahpeton Daily News - August 24th, 2017
- Cargill invests in 'clean meat' start-up - KARE - August 24th, 2017
- Stem-cell clinics are using a federal website as a marketing tool for unproven treatments, U of M bioethicist says - MinnPost - July 30th, 2017
- More than 60 US clinics have sold unproven stem cell therapies for heart failure - New York Post - July 30th, 2017
- Stemonix, a stem cell research firm, wins Minnesota Cup ... - November 27th, 2016
- Minnesotas Funding of Stem Cell Research Echoes Trend ... - October 29th, 2016
- Stem cell research Experts@Minnesota - October 18th, 2016
- Stem Cell FAQs - Minnesota Regenerative Medicine - October 7th, 2016
- Minnesota invests in regenerative medicine - Health Talk - October 7th, 2016
- Minnesota to resume umbilical cord blood donations ... - September 20th, 2016
- STEM Programs - Minnesota Zoo - September 5th, 2016
- Stem Cell Treatment - Minnesota Regenerative Medicine - August 18th, 2016
- Home - Minnesota Regenerative Medicine - August 18th, 2016
- Multipotent vs. pluripotent stem cells - Pathology Student - October 19th, 2015
- 2. Bone Marrow (Hematopoietic) Stem Cells [Stem Cell ... - October 19th, 2015
- Minnesota Man With ALS Hopes Stem Cells Save His Life ... - July 2nd, 2015
- Graduate Programs - MED - Stem Cell Institute, University ... - April 26th, 2015
- Atsushi Asakura, Ph.D. - MED - Stem Cell Institute ... - March 18th, 2015
- Bioelectricity Plays Key Role in Brain Development & Repair - March 13th, 2015
- Jakub Tolar, M.D., Ph.D. - MED - Stem Cell Institute ... - February 24th, 2015
- Stem Cell Web Focus - Nature Publishing Group : science ... - February 3rd, 2015
- Family: Experimental stem-cell treatment does wonders for Gordie Howe - December 20th, 2014
- Childrens hospital gets $25M - December 16th, 2014
- Stem Cell Malaysia Blog - December 12th, 2014
- Reduction of germ cells yields more zebrafish males - December 4th, 2014
- Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical ... - November 28th, 2014
- Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer - November 10th, 2014
- Anti-Cancer Drug Effective Against Common Stem Cell Transplant Complication - October 24th, 2014
- $25M gift prompts University pediatric hospital name change - October 16th, 2014
- Becoming a blood stem cell or bone marrow donor ... - October 3rd, 2014
- New heart built with stem cells - YouTube - September 27th, 2014
- Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial - September 12th, 2014
- Researchers find animal model for understudied type of muscular dystrophy - August 30th, 2014
- Minnesota Stem Cell Therapy | Stem Cell Treatments - August 29th, 2014
- Stem Cell FAQs - MED - Stem Cell Institute, University of ... - August 22nd, 2014
- Home - MED - Stem Cell Institute, University of Minnesota - August 22nd, 2014
- Stem cells | Health Sciences - University of Minnesota - August 22nd, 2014